Drugs / Autologous WT1 TCR transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02550535 | Sep 2015 → May 2018 | acute myeloid leukemia, myelodysplastic syndrome | Cell Medica Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous WT1 TCR transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02550535 ↗ |
| Modality | Cell therapy | “WT1 TCR-transduced T cells” NCT02550535 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT02550535 ↗ |
| Target | WT1 | “recognize fragments of a protein called WT1 (Wilms' tumour 1)” NCT02550535 ↗ |